Access to treatments:
The European Union - The harmonisation of the pharmaceutical industry regulatory processes and the EMEA (European Medicines Evaluation Agency). So that treatments, once approved by the EMEA, should be available in all member states at the same time.
The Applicant States to the Union, that once approved all treatments are fully
available.
In the developing world - see our separate position paper.
Clinical Trials.
The enlarged EU borders with the Ukraine, Russia and other states, and public health implications.
Biotechnology, Bioethics and genetic engineering. Stem Cell Research.
Pharmaceutical drug pricing, differential pricing, parallel trading & patent protection.
Standards of care and in-hospital treatment across Europe.
Issues
of concern
